Clinical trials: Oxycodone, completed
Pain
Fixed-dose Combination of Oxycodone [OXIcodona] + IbuproFEN in Pain Relief After Third Molar Extraction
A clinical, multicenter, randomized, parallel-group, double-blind, double-dummy, comparative study of non-inferiority. ⚠️Study will only be conducted in research centers in Brazil (please do not send e-mail if your center is…
- Trial name
- OXIFEN (NCT05081102)
- Testing
- FDC of oxycodone 5 mg/ibuprofen 400 mg, Tylex
- Where
- Brazil
- Volunteers
- 288 people, healthy volunteers welcome
- Sponsor
- Eurofarma Laboratorios S.A.
Hernia, Inguinal, Post Operative Pain
Herniorrhaphy for Postoperative Pain
Subjects receive either CPL-01, positive control, or negative control after herniorrhaphy and are then followed.
- Trial name
- NCT05813847
- Testing
- local anaesthetic injection of CPL-01, Morphine (rescue medication), Acetaminophen (rescue medication)
- Where
- United States
- Volunteers
- 518 people
- Sponsor
- Cali Pharmaceuticals LLC
Bunion, Post-operative Pain
CPL-01 in the Management of Postoperative Pain After Bunionectomy
Subjects receive study drug during bunionectomy and are followed for pain and opioid use, with the hypothesis that those who receive CPL-01 will have less pain and less opioid use than either control arm.
- Trial name
- NCT05831449
- Testing
- Local anesthetic injection of CPL-01, Naropin, 0.5% Injectable Solution, Morphine rescue medication
- Where
- United States
- Volunteers
- 616 people
- Sponsor
- Cali Pharmaceuticals LLC
Acute Pain
A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy
The purpose of this study is to evaluate the efficacy and safety of Cebranopadol for acute pain after a bunionectomy.
- Trial name
- ALLEVIATE2 (NCT06423703)
- Testing
- Cebranopadol, Oxycodone IR
- Where
- 10 sites in United States
- Volunteers
- 240 people
- Sponsor
- Tris Pharma, Inc.
Healthy
A Study to Investigate the Pharmacodynamic Effect of Single Doses of MT-8554 in Healthy Subjects
The purpose of this study is to investigate the pharmacodynamic effect of single doses of MT-8554 in healthy subjects.
- Trial name
- NCT02536209
- Testing
- MT-8554 low dose, MT-8554 high dose, Oxycodone hydrochloride
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Healthy, Opioid Use
Buprenorphine-Fentanyl Interaction Study
An increase in overdose deaths has been attributed to widespread access to fentanyl and carfentanyl. The study is designed to determine if buprenorphine can change the respiratory depression response to intravenous (IV) fentanyl.
- Trial name
- NCT03747341
- Testing
- Buprenorphine Injectable Solution - Part A, Fentanyl - Part A, Ondansetron - Parts A + B
- Where
- Netherlands
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Indivior Inc.
Acute Pain
Assessment of PF614 Effects on Experimental Pain in the Cold Pressure Test (PF614-201)
The primary objective of the study is to evaluate the onset of analgesia following administration of a single oral dose of PF614 (50 mg or 100 mg) or placebo in healthy male subjects in an experimental pain model (cold pressor…
- Trial name
- CPT (NCT06629402)
- Testing
- PF614
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Ensysce Biosciences
Healthy
Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101)
PF614 is an oxycodone prodrug that is designed for extended-release of oxycodone comparable to OxyContin. This Single Ascending Dose (SAD) study is designed to assess the safety and pharmacokinetics (PK) of PF614 in comparison to…
- Trial name
- SAD (NCT02454712)
- Testing
- PF614, Oxycodone extended-release, Naltrexone Hydrochloride
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Ensysce Biosciences
Healthy Volunteers
Evaluation of Oral PF614 Relative to OxyContin (PF614-102)
This is a single-center study incorporating 2 parts: A Multiple Ascending Dose Study (Part A) and a comparative Bioavailability/Bioequivalence and Food Effect study (Part B).
- Trial name
- NCT05043766
- Testing
- PF614, Naltrexone Hydrochloride, OxyContin
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Ensysce Biosciences
Pharmacokinetics
Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)
A single dose study to assess the pharmacokinetics (PK) of oxycodone, when PF614 is solution is administered alone and with nafamostat as an immediate-release (IR) solution and/or extended-release (ER) capsule prototypes.
- Trial name
- MPAR-101 (NCT05090280)
- Testing
- PF614 solution, Naltrexone Hydrochloride, Nafamostat Mesylate
- Where
- United States
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Ensysce Biosciences
Recreational Drug Use
A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-103)
The purpose of this study is to examine the abuse potential and pharmacokinetics of PF614 compared with a non-abuse deterrent, commercially available, immediate release (IR) oxycodone hydrochloride (HCl) formulation and placebo.
- Trial name
- NCT05567354
- Testing
- PF614, Oxycodone
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Ensysce Biosciences
Recreational Drug Use
A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104)
This will be a randomized, double-blind, placebo- and active-controlled, 5-way crossover study to evaluate the abuse potential, safety and pharmacokinetics of orally administered PF614 relative to oxycodone IR (immediate-release)…
- Trial name
- NCT05571345
- Testing
- PF614, Oxycodone Hydrochloride 40 mg
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Ensysce Biosciences
Abuse Potential
Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users
The purpose of this study is to assess the abuse potential of gabapentin enacarbil immediate release capsules taken alone and in combination with oxycodone in healthy adult, non-dependent, recreational opioid users.
- Trial name
- NCT06247488
- Testing
- Oxycodone 20 mg, GE-IR 200 mg, GE-IR 450 mg
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Arbor Pharmaceuticals, Inc.
Pain
Cebranopadol Effects on Ventilatory Drive, Central Nervous System (CNS) and Pain.
Opioids are potent painkillers but come with serious adverse effects ranging from addiction to potentially lethal respiratory depression via activation of μ-opioid receptors (MOP) at specific sites in the central nervous system.
- Trial name
- NCT05491785
- Testing
- Cebranopadol 600 µg, Cebranopadol 800 µg, Cebranopadol 1000 µg
- Where
- 2 sites in Netherlands
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tris Pharma, Inc.
Postsurgical Pain
Study in Subjects Undergoing Complete Abdominoplasty
Phase 2, single center, randomized, double-blind, placebo-controlled, parallel design study of CA-008 vs. placebo in subjects undergoing an elective C-ABD under general anesthesia supplemented with a bupivacaine hydrochloride…
- Trial name
- NCT03789318
- Testing
- CA-008 5 mg, Bupivacaine Hydrochloride, Hydromorphone
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Concentric Analgesics
Abuse Potential
Study Evaluating Abuse Potential of Lyrica® in Healthy Non-Drug Dependent Recreational Opioid Users
This is a Phase 4 clinical study in healthy non-drug dependent recreational opioid users to assess the abuse potential of Lyrica when taken alone or in combination with oxycodone.
- Trial name
- NCT05053126
- Testing
- Pregabalin 300mg, pregabalin 450 mg, Pregabalin 300 mg with oxycodone 20 mg
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Viatris Specialty LLC
Abuse Potential
Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users
This will be a randomized, double-blind, double-dummy, placebo- and active-controlled, 6 treatment, 6-period crossover single-dose, Williams square design study in healthy male and/or female adult, non-drug-dependent recreational…
- Trial name
- NCT05319756
- Testing
- gabapentin 600 mg, gabapentin 1200 mg, gabapentin 600 mg and oxycodone HCl 20 mg
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Viatris Specialty LLC
Pain, Nausea
A Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg for Acute Pain and the Prevention of OINV
To determine the analgesic efficacy of CL-108 5 mg by comparison with placebo and the anti-emetic efficacy of CL-108 5 mg by comparison with hydrocodone 5 mg/acetaminophen 325 mg.
- Conditions
- Pain, Nausea, Vomiting
- Trial name
- NCT03657810
- Testing
- CL-108 5 mg, Norco
- Where
- 5 sites in United States
- Volunteers
- 349 people
- Sponsor
- Charleston Laboratories, Inc
Pain
Evaluate The Pharmacokinetics and Safety Of Oxycodone Oral Solution In Pediatric and Adolescent Subjects
The objective of this study is to characterize the pharmacokinetics and to evaluate the safety of single and multiple doses of Oxycodone Oral Solution in pediatric and adolescent subjects for postoperative pain.
- Trial name
- NCT01959204
- Testing
- Oxycodone
- Where
- 9 sites in United States
- Volunteers
- 97 people
- Sponsor
- VistaPharm, Inc.
Neurologic Impairment by Opioids
Non-intrusive Detection of Temporary Neurologic Impairment by Opioids
The investigators aim to prove the feasibility of a non-invasive means to identify temporary neurological impairment resulting from the use of a commonly prescribed opioid by identifying an oculomotor biosignature associated with…
- Trial name
- NCT05489601
- Testing
- Oxycodone
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Zxerex Corporation